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Abstract
Microsatellite instability (MSI) is present in 15–20% of primary colorectal cancers. MSI status is assessed to detect Lynch
syndrome, guide adjuvant chemotherapy, determine prognosis, and use as a companion test for checkpoint blockade inhibitors.
Traditionally, MSI status is determined by immunohistochemistry or molecular methods. The Idylla™ MSI Assay is a fully
automated molecular method (including automated result interpretation), using seven novel MSI biomarkers (ACVR2A, BTBD7,
DIDO1, MRE11, RYR3, SEC31A, SULF2) and not requiring matched normal tissue. In this real-world global study, 44 clinical
centers performed Idylla™ testing on a total of 1301 archived colorectal cancer formalin-fixed, paraffin-embedded (FFPE) tissue
sections and compared Idylla™ results against available results from routine diagnostic testing in those sites. MSI mutations
detected with the Idylla™MSI Assay were equally distributed over the seven biomarkers, and 84.48% of the MSI-high samples
had ≥ 5 mutated biomarkers, while 98.25% of the microsatellite-stable samples had zero mutated biomarkers. The concordance
level between the Idylla™MSIAssay and immunohistochemistry was 96.39% (988/1025); 17/37 discordant samples were found
to be concordant when a third method was used. Compared with routine molecular methods, the concordance level was 98.01%
(789/805); third-method analysis found concordance for 8/16 discordant samples. The failure rate of the Idylla™ MSI Assay
(0.23%; 3/1301) was lower than that of referenced immunohistochemistry (4.37%; 47/1075) or molecular assays (0.86%; 7/812).
In conclusion, lower failure rates and high concordance levels were found between the Idylla™ MSI Assay and routine tests.
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Introduction
Colorectal cancer (CRC) is a serious health problem in west-
ern countries. In 2018 in Europe, CRC was the second most
commonly diagnosed malignancy (500,000 cases) and also
the second leading cause of cancer death (243,000 deaths),
with a total of 4.51 million new cancer cases overall [1, 2].
The general population has a lifetime risk for developing CRC
of about 5% [3, 4].
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Environmental and hereditary factors contribute to its de-
velopment, as demonstrated by the accumulation of mutations
in oncogenes, tumor suppression, and mismatch repair defi-
ciency. CRCs comprise a group of molecularly heterogeneous
tumors that are characterized by a range of genomic and
epigenomic alterations. A significant proportion of colorectal
carcinomas show chromosomal instability and follow the clas-
sical morphological progression sequence in the adenoma/
carcinoma pathway genes [5, 6].
Microsatellite instability (MSI) was initially noted in can-
cers of patients with Lynch syndrome, often called hereditary
non-polyposis colon cancer syndrome (HNPCC), but also in
some sporadic colon cancers [7–10]. Microsatellite instability
high (MSI-H) is a phenomenon present in approximately 15 to
20% of primary CRCs and is characterized by mutation or
methylation of mismatch repair (MMR) genes [11]. CRC pa-
tients from HNPCC kindred have an inherited germline mu-
tation in eitherMLH1,MSH2,MSH6, PMS2, orEPCAM. This
germline alteration is combined with a somatic alteration in
the contralateral allele, fulfilling Knudson’s two hits [12]. The
MSI-associatedMMR deficiency leads to the accumulation of
myriads of mutations in coding and non-coding DNA se-
quences, generating instability in the microsatellite regions,
which expand or contract with the insertion or deletion of
repetition units, characteristic of the hypermutator phenotype.
Approximately 20 to 25% of MSI-H CRCs represent
HNPCC-related tumors, while the remaining 75 to 80% cor-
responds to sporadic CRCs [13]. Thus, MSI-H is a critical
marker for the diagnosis of HNPCC.
It has been suggested that identification of MSI in CRC is
important for assessment of prognosis and treatment stratifica-
tion. Fluorouracil (5-FU) is a component of the standard treat-
ment for patients with stage II CRC. There is evidence in the
literature suggesting that MMR deficiency is associated with 5-
FU resistance in CRC cells. Thus, MSI testing is helpful in the
clinical assessment and management of CRC patients because
MSI-H tumors are associated with a favorable prognosis after
surgical resection and do not have improvement in survival
with the addition of adjuvant 5-FU therapy [14].
MSI-H tumors may be targets for immunotherapeutic treat-
ments. Immune checkpoint inhibitors have moved the field of
immuno-oncology to the forefront of cancer treatment, and
immune checkpoint blockade therapies have been FDA-
approved for the treatment of a broad range of tumor types,
including CRC. The presence of MSI is now established as a
biomarker for response to immunotherapy; Brahmer sug-
gested that MSI-H tumors are hypermutated and express nu-
merous neoantigens caused by mutations and a high number
of frameshifts that induce immune responses by tumor-
infiltrating lymphocytes (TILs) [15].
Several techniques can be used for MSI testing.
Microsatellite insertions and deletions (indels) can be demon-
strated by extracting DNA from formalin-fixed, paraffin-
embedded (FFPE) normal and CRC tumor tissue and subse-
quent amplification of specific microsatellite sequences by
polymerase chain reaction (PCR) and fragment size analysis
[16]. Bacher identified an optimal set of markers that provided
maximal sensitivity and specificity for MSI-H tumors and
incorporated them into a multiplex fluorescent assay for a
simple, rapid, and accurate detection of MSI-H tumor pheno-
type. [17] The resulting Promega assay forMSI testing includ-
ed five nearly monomorphic mononucleotide repeat markers:
BAT-25, BAT-26, NR-21, NR-24, andMONO-27. All of them
are mononucleotide repeat markers previously reported to
have greater sensitivity and specificity for MMR deficiency
than dinucleotide markers. An updated version of the assay
includes the five mononucleotide markers and two highly
polymorphic pentanucleotide repeat markers (Penta C and
Penta D).
Immunohistochemistry (IHC) shows a 95% sensitivity for
DNA MMR deficiency, and this technique consists of detect-
ing the expression of proteins from the major DNA MMR
genes (MSH2 and MLH1) and from the minor DNA MMR
genes (MSH6 and PMS2). It is important to keep in mind that
loss of expression of any of theMMR proteins can also be due
to bi-allelic somatic inactivation.
Both IHC and the previously mentioned MSI DNA tests
are sensitive and specific, but there is room for improvement.
The reported sensitivity of MSI DNA tests is 89% forMLH1/
MSH2 and 77% for MSH6, while the reported sensitivity of
IHC is 77 to 83%. [20] Concordance between both methods is
over 92%. [17–20]
The updated relevance of MSI in CRC, not only by identi-
fying HNPCC patients that present as sporadic CRC but also
in prognosis and in treatment decisions regarding adjuvant
chemotherapy (5-FU) and immunotherapy, justifies efforts
to improve the currently available techniques. The search for
optimal methods for MSI testing, with simpler workflow and
less requirements regarding tumor tissue availability is an ad-
ditional driver for this research.
Whole-genome and whole-exome sequencing of MMR-
deficient tumors (endometrial cancer and CRC) and of normal
cells led to the identification of 59 new biomarkers being
indicative for MSI status [21]. Based on this panel, the
Idylla™ MSI assay was developed, which contains seven
novel MSI biomarkers selected on their stability over different
cancer types and ethnicities, and showing high diagnostic per-
formance: ACVR2A, BTBD7, DIDO1, MRE11, RYR3,
SEC31A, and SULF2 [22]. When tested on smaller sets of
CRC FFPE tissue samples, the Idylla™ MSI assay showed
concordance rates of > 97.5% with previous routine IHC and
molecular results [22–24]. The current study describes a
multi-center evaluation (44 centers) of the performance of
the Idylla™ MSI assay in comparison with IHC or with mo-
lecular tests including the Bethesda/Promega MSI Analysis
System on 1301 archival CRC FFPE tissue sections.
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Materials and methods
Tissue sample collection
For this study, archived clinical FFPE tissue material of 1301
CRC patients was selected by the participating clinical cen-
ters. The samples were obtained from 44 clinical centers
around the globe (Table 1).
The use of the patient samples was approved by the respec-
tive local Ethics Committees and was in compliance with the
Declaration of Helsinki. The participating centers received
proper training to perform the Idylla™ MSI assay.
The Idylla™ MSI assay was performed on slides/slices
from the same block of archived clinical FFPE tissue material
used previously for testing with routine reference methods,
and slices/slides were taken as close as possible to the sample
used for these routine reference methods.
Idylla™ MSI assay
The Idylla™MSI assay, performed on the Idylla™ System, is
intended for the qualitative detection of a panel of seven
monomorphic homopolymer biomarkers for identification of
microsatellite instability in human cancer, resulting in identi-
fication of the MSI status of the sample. These novel MSI
markers used in the Idylla™ MSI assay are (with locus be-
tween brackets): ACVR2A (2q22.3-q23.1), BTBD7
(14q32.12), DIDO1 (20q13.33), MRE11 (11q21), RYR3
(15q13.3-q14), SEC31A (4q21.22), and SULF2 (20q13.12).
They were selected to be short and monomorphic, in order
to be compatible with PCR detection by means of probes
rather than analysis by means of capillary electrophoresis.
The Idylla™MSI assay uses FFPE material from human can-
cer tissue, which is directly loaded in the cartridge.
The tissue area of the FFPE specimen should be between
50 and 600 mm2 when 5-μm FFPE tissue sections are used
and between 25 and 300 mm2 when using 10-μm FFPE tissue
sections; up to five FFPE tissue sections can be used to meet
this requirement. If a specimen contains less than 20% neo-
plastic cells, macro-dissection has to be performed. The
Idylla™ MSI assay automates the entire process from FFPE
sample preparation to reporting of MSI status, including lib-
eration of nucleic acids from FFPE material, PCR amplifica-
tion, and analysis by high-resolution melting detection. The
total turnaround time of the Idylla™ MSI assay is less than
150 min.
According to the manufacturer’s assay instructions, the
MSI status of the sample can be determined with high confi-
dence if at least five valid marker-specific fluorescence pro-
files could be fully analyzed (otherwise the MSI status will be
called “invalid”). At least two mutant markers will result in a
status being “MSI-H” (microsatellite instability high), other-
wise the status will be scored as “MSS” (microsatellite stable).
IHC and molecular routine reference methods
IHC analysis of the expression of the marker genes MLH1,
MSH2, MSH6, and PMS2 in FFPE tissue material was per-
formed using routine standard protocols and equipment, in-
cluding commercial antibodies from Ventana (Roche
Diagnostics, Rotkreuz, Switzerland) and Dako (Agilent,
Santa Clara, CA), and systems from Ventana and Leica
Biosystems (Wetzlar, Germany). There was no central re-
review and that the results of these routine tests were reviewed
in retrospect.
Investigation of colorectal FFPE tissue material with the
PCR-based Promega MSI Analysis System v1.2 (RUO),
which analyzes the five MSI markers from the revised
Bethesda panel, i.e., NR-21, NR-24, BAT-25, BAT-26, and
MONO-27, was performed according to the procedures imple-
mented in every individual lab (Table 1). Alternatively, PCR
analysis was performed on customized molecular MSI panels
including markers from the following list: NR-21, NR-22, NR-
24, NR-27, BAT-25, BAT-26, BAT-40, D2S123, D5S346,
D10S197, D13S153, D17S250, D18S58, D18S69, CAT25,
HSP110, TGFbetaRII, and MYCL1.
For the molecular reference methods, criteria for defining
MSI-H and MSS were according to the manufacturer’s assay
instructions and each laboratory procedure. For the IHC ref-
erence methods, variability has been detected, as some centers
defined the loss of one protein marker as being sufficient to
call it deficient MMR, whereas other centers defined the loss
of a paired protein marker. In this the study, the site-specific
standard laboratory procedure was followed to present a real-
life data cohort.
Statistical analysis
The agreement between the Idylla™MSI assay and the com-
parator methods (IHC or PCR-based assays on MSI panels)
was evaluated based on point estimates for Overall, Positive,
and Negative Percent Diagnostic agreement together with
95% one-sided Wilson-score confidence intervals.
Results
FFPE tissue samples
The MSI status of archived clinical FFPE tissue sections orig-
inating from 1301 patients with CRC was determined using
the Idylla™MSI assay at 44 centers. To increase the percent-
age of the tumor area for samples with low tumor cellularity to
≥ 20% as required by the instructions for use of the Idylla™
MSI assay, macro-dissection was performed in 552 cases. The
sample characteristics are summarized in Table 2.
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IHC panel Molecular method panel
Department of Pathology, Hospital
Universitari Vall d’Hebron




BAT-25, BAT-26, NR-21, NR-24, MONO-27




BAT-25, BAT-26, NR-21, NR-24, NR-27, HSP110





Hôpital Erasme Service d’Anatomie
Pathologique




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Addenbrooke’s Hospital AND Department
of Cellular Pathology (Oxford
University Hospitals NHS Foundation
Trust)
Cambridge,
UK and Oxford, UK
30 NA BAT-25, BAT-26, NR-21, NR-24, MONO-27
Institute of Pathology,
University Hospital Cologne




BAT-25, BAT-26, NR-21, NR-22, NR-27 OR
BAT-25, BAT-26, D2S123, D5S346, D17S250
OR BAT-25, BAT-26, BAT-40, NR-21, NR-22,
NR-24, NR-27, D2S123, D5S346, D17S250,
D10S197, D18S58, D13S153, MYCL1






Institut für Pathologie, Abteilung für
Molekularpathologie




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Platform of Somatic Oncology of
Burgundy, CHU de Dijon




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Ev. Krankenhaus Bethesda,
Institut für Pathologie




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Pathology, HUSLAB,
Helsinki University Hospital















BAT-25, BAT-26, NR-21, NR-24, MONO-27




BAT-25, BAT-26, NR-21, NR-24, MONO-27 OR
BAT-25, BAT-26, NR-21, NR-22, NR-24




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Städtisches Klinikum Karlsruhe gGmbH,
Pathologisches Institut
Karlsruhe, Germany 30 MLH1,
MSH2,
BAT-25, BAT-26, D2S123, D5S346, D17S250






IHC panel Molecular method panel
PMS2,
MSH6




BAT-25, BAT-26, NR-21, NR-22, NR-24 OR
BAT-25, BAT-26, NR-21, NR-24, NR-27
Shaukat Khanum Cancer Hospital and
Research Centre











BAT-25, BAT-26, D2S123, D5S346, D17S250
GenoMed - Diagnósticos de Medicina
Molecular, SA
Lisbon, Portugal 30 MLH1,
MSH2,
MSH6
BAT-25, BAT-26, NR-21, NR-24, MONO-27




BAT-25, BAT-26, NR-21, NR-24, MONO-27




BAT-25, BAT-26, D2S123, D5S346, D17S250




BAT-25, BAT-26, NR-21, NR-24, MONO-27




BAT-25, BAT-26, NR-21, NR-24, MONO-27
Peter MacCallum Cancer Centre Melbourne, Australia 27 NA BAT-25, BAT-26, NR-21, NR-22, D2S123,
D5S346, D17S250, CAT25




BAT-25, BAT-26, NR-21, NR-22, NR-24,
MONO-27









BAT-25, BAT-26, NR-21, NR-24, MONO-27










Department of Medicine (DIMED) -
University of Padua




BAT-25, BAT-26, BAT-40, NR-21, NR-24,
D2S123, D5S346, D17S250, D18S58,
TGFbetaRII
Pforzheim, Germany 23 NA






IHC panel Molecular method panel










BAT-25, BAT-26, NR-21, NR-24, MONO-27
CHU Reims, Laboratoire de Biopathologie
HMB, Hôpital Maison Blanche




BAT-25, BAT-26, NR-21, NR-24, MONO-27














BAT-25, BAT-26, NR-21, NR-24, MONO-27







Virgen del Rocío Hospital




BAT-25, BAT-26, NR-21, NR-24, MONO-27













BAT-25, BAT-26, NR-21, NR-24, MONO-27





Department of Clinical Pathology and
Cytology, Karolinska University
Hospital, Stockholm, Sweden




BAT-25, BAT-26, NR-21, NR-24, MONO-27












BAT-25, BAT-26, NR-21, NR-24, MONO-27
NA, not assessed
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Idylla™ MSI assay on archived clinical samples
All 1301 samples had previously been tested with at least one
routine reference method, and 586 of the samples had been
tested with both IHC and a molecular reference method. In
total, 1075 samples had been tested before with IHC and 812
with molecular methods. Of the 812 samples tested with mo-
lecular methods, 101 had been tested with the original
Bethesda panel, 525 with the revised Bethesda panel, and
186 against a range of other microsatellite biomarker panels
(Table 1).
Of the 1301 samples tested with the Idylla™ MSI assay,
612 were found to be MSI-H and 686 to be MSS, while for
three samples, the result was invalid. The majority (84.48%)
of the MSI-H samples had five or more mutated biomarkers,
and the vast majority (98.25%) of the MSS samples had zero
mutated biomarkers (Table 3). Of the biomarkers tested by the
Idylla™ MSI assay, MRE11 gave most of the invalid results,
while DIDO1 did not result into any invalids; mutations were
rather equally distributed over all of the seven assessed bio-
markers (Table 4).
The failure rate of the Idylla™ MSI assay was 0.23%
(3/1.301), while the reference methods had higher failure rates
of 4.37% (47/1075) for IHC and 0.86% (7/812) for the routine
molecular methods. Routine method failure rates might how-
ever be an underestimation as the current analysis was done
retrospectively on samples with known routine results.
To investigate concordance levels, the results of the
Idylla™ MSI assay were compared with the results of the
routine reference methods, i.e., IHC or molecular MSI
panels, performed before on slides/slices of the same
FFPE block. According to the protocol, the FFPE slides/
slices used for the Idylla™ MSI assay had to be taken as
close as possible (within the block) to the slides/slices used
to generate the reference result. Although this was not al-
ways the case, sections were close in the vast majority of
cases. Also, a hematoxylin and eosin (H&E) staining to
confirm of the presence of tumor tissue in the sample was
not done at all sites.
Concordance of Idylla™MSI assay results with routine
IHC results
Compared to IHC, the results of 37 of the 1025 samples tested
(valid calls only) with the Idylla™ MSI Assay on the same
FFPE block were reported to be discordant; i.e., a concor-
dance of 96.39% (CI: 95.06–97.37%) was obtained (Table 5).
For 21 of these 37 discordant samples, results of molecular
methods were also available, and in 14 cases, these results
were concordant with the results of the Idylla™ MSI Assay
(i.e., 5 MSI-H and 9 MSS results). Of the 7 samples having
discordant results between the Idylla™ MSI assay and both
routine reference methods, 2 samples were retested with the
Idylla™MSI assay, and this retest confirmed the results of the
reference methods (i.e., deficient mismatch repair (dMMR)
and MSI-H).
Of the remaining 16 of the 37 discordant samples, which
were only tested with IHC as a reference, a retest result on
consecutive slides/slices with the Idylla™ MSI assay was
available for 1 sample and found to be concordant with IHC
(i.e., MSI-H/dMMR).
Table 2 Characteristics of the 1301 study samples
























% Tumor cells (after macro-dissection)
< 10 4*
10– < 20 20*
20– < 30 76
30– < 40 153
40– < 50 135
50– < 60 158
60– < 70 165
70– < 80 146




*Values not according to the specifications of the Idylla™ MSI assay
instructions; however, for all these samples, Idylla™ MSI assay results
were found concordant with results of previous routine reference methods
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For the 47 of the 1025 samples tested that had invalid or
doubtful IHC calls, molecular method results for the same
tissue block were available in 45 cases, of which 42 were
found to be concordant with the Idylla™ MSI Assay (i.e., 9
MSI-H/dMMR and 33 MSS/proficient mismatch repair
(pMMR)).
Concordance of Idylla™MSI assay results with routine
molecular method results
Compared to molecular methods, the results of 16 of the 805
samples tested (valid calls only) with the Idylla™ MSI assay
on the same FFPE block were reported to be discordant; i.e., a
concordance of 98.01% (CI: 96.80–98.77%) was obtained
(Table 5).
For 12 of these 16 discordant samples, IHC had also been
performed previously, and in 4 cases, these results were found
to be concordant with the Idylla™MSI assay (i.e., 4 MSS); in
these 4 cases, the marker panel used in the molecular reference
method encompassed dinucleotide repeats. Of the 8 samples
having discordant results between the Idylla™MSI assay and
both routine reference methods, 2 samples were retested with
the Idylla™ MSI assay confirming reference results as de-
scribed above.
Table 4 Idylla™ MSI assay calls per biomarker
ACVR2A BTBD7 DIDO1 MRE11 RYR3 SEC31A SULF2
Overall
Mutant 579 514 576 505 411 373 457
Wild-type 718 782 725 780 887 926 840
Invalid 4 5 0 16 3 2 4
Total 1301 1301 1301 1301 1301 1301 1301
MSI-H samples
Mutant 575 513 570 504 411 373 457
Wild-type 37 99 42 107 201 239 154
Invalid 0 0 0 1 0 0 1
Total 612 612 612 612 612 612 612
MSS samples
Mutant 4 1 6 1 0 0 0
Wild-type 680 683 680 672 685 686 685
Invalid 2 2 0 13 1 0 1
Total 686 686 686 686 686 686 686
Invalid samples
Mutant 0 0 0 0 0 0 0
Wild-type 1 0 3 1 1 1 1
Invalid 2 3 0 2 2 2 2
Total 3 3 3 3 3 3 3
Table 3 Number of Idylla™ MSI Assay “mutant” calls
MSI status Number of samples Number of mutant markers Number of samples % of MSI-H
MSS 686 0 674 NA
1 12 NA






Invalid 3 NA NA NA
Total 1301
NA, not applicable
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Of the remaining 4 of the 16 discordant samples, which
were only tested with molecular methods as a reference, a
retest result on consecutive slides/slices with the Idylla™
MSI assay was available for 2 samples. For 1 of these 2 sam-
ples, the retest result was concordant with the result of the
molecular method (i.e., MSI-H); improper cutting of the tu-
mor from the original block is suspected to have caused the
discordant MSS result for the Idylla™ MSI assay. For the
second sample, the retest still detected an MSI-H status dis-
cordant with the MSS status determined with the Promega
MSI Analysis System; however, an additional IHC analysis
of this sample found dMMR, which is concordant with the
Idylla™ MSI assay result.
For the 7 samples with invalid or doubtful results by a
molecular method, IHC results were available in 3 cases,
which were found to be concordant with the Idylla™ MSI
assay results (i.e., 1 MSI-H/dMMR and 2 MSS/pMMR).
Discussion
In the current article, we report the results of a multi-center
study of the Idylla™MSI assay on archival FFPE CRC tumor
tissue from different countries around the globe, and hence
different ethnicities, to assess concordance with previously
obtained results from both IHC and molecular tests. A total
of 1301 samples were analyzed in 44 independent centers
selected from 25 different countries. A total of 612 clinical
samples were classified by the Idylla™ MSI assay as MSI-H
and 686 samples asMSS, while only 3 cases were invalid. The
samples had been tested before either by IHC (1075 cases)
and/or by molecular methods (812 cases).
Discordant results between the Idylla™MSI assay and IHC
were detected in 37 of 1025 cases, resulting in a concordance
level of 96.39%. Discordance between the Idylla™MSI Assay
and other molecular methods, including the Promega MSI
Analysis System, was found in 16 of the 805 cases, which
represents a 98.01% concordance. Of the 1301 samples, 586
were tested with both IHC and molecular methods, which en-
abled comparison of the results of three methods. As a result, of
the 37 samples discordant between the Idylla™MSI assay and
IHC, 14 were concordant between the Idylla™MSI assay and
molecular methods, and conversely, of the 16 samples discor-
dant between the Idylla™MSI assay and molecular methods, 4
were concordant between the Idylla™ MSI Assay and IHC.
Due to a restricted amount of archived sample tissue available,
only 5 of the discordant results were retested with the Idylla™
MSI assay, and no further analysis with other methods was
performed. The excellent concordance levels found are in line
with previously published levels for the Idylla™ MSI assay
[22–25]. In these studies with smaller sample sets and more
standardized routine reference methods, concordance levels of
the Idylla™ MSI assay were 95.00–98.71% with IHC, 99.05–
100.00% with molecular methods, and 99.05% with next-
generation sequencing.
The mutations were found to be rather equally distributed
over the seven biomarkers of the Idylla™MSI assay. The vast
majority of the MSS calls had no mutations in the seven bio-
markers, while the majority of the MSI-H calls had at least five
mutated biomarkers. Taking also into account the global multi-
Table 5 Comparison between the results of the Idylla™ MSI assay and the results of routine IHC assays or of routine molecular methods
IHC
dMMR pMMR Invalid Doubtfula Total
Idylla™ MSI-H 501 12 1 10 524
MSS 25 487 6 30 548
Invalid 2 1 0 0 3
Total 528 500 7 40 1075
Idylla™ Performance Positive agreement 501/526 = 95.24% (CI: 93.08–96.76%)
Negative agreement 487/499 = 97.59% (CI: 95.84–98.62%)
Overall agreement 988/1025 = 96.39% (CI: 95.06–97.37%)
Molecular methods
MSI-H MSS Invalid Doubtfula Total
Idylla MSI-H 381 4 0 2 387
MSS 12 408 1 2 423
Invalid 0 0 2 0 2
Total 393 412 3 4 812
Idylla™ Performance Positive agreement 381/393 = 96.95% (CI: 94.74–98.24%)
Negative agreement 408/412 = 99.03% (CI: 97.53–99.62%)
Overall agreement 789/805 = 98.01% (CI: 96.80–98.77%)
aDoubtful results have been reported by the involved clinical site as doubtful based on their site-specific evaluation criteria, which were not standardized
across sites
859Virchows Arch (2021) 478:851–863
center, these findings not only underscore the high and consis-
tent incidence of the seven assessed biomarkers in CRC but
also their stability across different regions worldwide (exclud-
ing Africa and North America) and hence indirectly different
ethnicities. Of the 12 MSS samples with only one mutated
Idylla™ MSI biomarker, 5 had an MSI-H call when using the
routine reference methods, indicative for a low Idylla™ false-
negative rate. Moreover, of these 5 samples, 1 was reported to
have < 5% tumor cells, which is below the minimal percentage
stipulated in the Idylla™MSI assay instructions for use, and for
3 of these samples, the exact neoplastic cell content was un-
known. Therefore, too low levels of tumor cells in these sam-
ples may have been the reason why the Idylla™MSI assay did
only find one biomarker to be mutated.
It is highly important that assay instructions are followed,
and for sure that the minimal amount of neoplastic cells (i.e.,
20% for the Idylla™ MSI assay) has been obtained. As in the
current study the Idylla™MSI assaywas performed on archival
tissue samples, there is indeed a chance that some samples did
not contain tumor tissues. In this respect, the protocol required
sampling of slices/slides to happen as close as possible (within
the block) to the slides/slices used to generate the reference
result. This was not always the case and may have contributed
to a number of MSS calls by the Idylla™MSI assay that were
not concordant with the MSI-H call of the reference method. In
addition, an H&E confirmation of the presence of tumor tissue
in the sample was absent in many cases.
Another disadvantage of our multi-center study of 44 centers
in multiple countries is that the IHC and molecular routine
reference methods used showed variability in marker panels,
providers, protocols, interpretation, and scoring criteria, which
may have influenced their outcome and as such the concor-
dance rates found. However, this setup enabled testing and
benchmarking of the Idylla™MSI assay in a real-world setting,
which was the main goal of this study. It also showed the stable
performance of the Idylla™ MSI assay in different laboratory
environments.
The failure rate of the Idylla™ MSI assay was only 0.23%,
which is lower than that of IHC (4.37%) or of the routine
molecular MSI tests (0.86%). However, the actual failure rates
of the reference methods may be considerably higher, as the
samples in the current study were retrospectively selected based
on the availability of valid results from at least one reference
method. The lower failure rate compared to other molecular
methods might be explained by the shorter amplicons analyzed
in the Idylla™ MSI assay (below 100 base pairs) compared
with the Promega MSI Analysis System (150 base pairs or
higher), which results in an improved performance of Idylla™
on bad-quality samples (highly fragmented DNA and/or low-
input DNA samples). IHC needs visual result interpretation of
immunostaining color patterns, which is done via site-
dependent interpretation strategies and cutoff values that also
introduce a subjective pathologist-dependent aspect. These
issues may lead to higher numbers of invalid/doubtful results
as we have observed in the current study, with 40 doubtful IHC
results being recorded at seven sites. In contrast, the Idylla™
MSI assay’s software decision tree is fully automated, and
therefore, results are not prone to subjective interpretation. A
previous analysis of consecutive sections of 182 samples with
three methodologies revealed a higher number of invalid results
for the PromegaMSIAnalysis System (3.8%) and IHC (13.2%)
compared with the prototype Idylla™ MSI assay (2.2%) [26].
As to interpretation strategies used for IHC results in the current
study, the majority of the sites classified samples with at least
one deficient marker as dMMRbut two sites needed at least two
deficient markers to do so. In 18 cases, not all four biomarkers
(MLH1, MSH2, MSH6, PMS2) were tested with IHC, and of
these, three results did not confirm theMSI-H status determined
with the Idylla™ MSI assay.
Overall, IHC testing is highly specific and sensitive, with
easy performance and cost effectiveness [20]. However, there
are also limitations. For example, some mutations that are not
detected by the antibodies used in IHC still result in expression
of nonfunctional proteins. More importantly, poor pre-
analytical conditions, particularly delayed or prolonged fixa-
tion, may be responsible for difficulties in interpretation in some
cases. As a general rule, it is important to verify internal control
staining in non-neoplastic cells to enable interpretation of the
results. One additional advantage of IHC is the fact that the
absence of expression of a specific MMR protein can direct
germline testing to that specific gene.
The Idylla™ MSI assay differs from the Promega MSI
Analysis System due to its seven alternative biomarkers. It
has been suggested that the seven selected regions might show
consistent wild-type profiles over different ethnicities, while for
the Bethesda markers, there is an actual variation between dif-
ferent ethnicities [27]. Noteworthy, the current study was not
specifically designed to address that issue. Therefore, to obtain
a correct interpretation of the results, a comparison between a
matched normal tissue and the tumor tissue profile for each
patient needs to be performed when testing against the
Bethesda panel, which is not the case for the Idylla™ MSI
Assay that only requires tumor tissue testing, hence a simplified
procedure. Further differences are that routine molecular
methods have long turnaround timeswith cumbersome, lengthy
workflows usually requiring batching of samples, and that cap-
illary sequencing instrumentation is required for these methods.
The Idylla™ MSI assay in contrast demonstrates great speci-
ficity in a highly automated simplified workflow compared to
current methods, with reliable results within approximately 150
min. Although the study was not designed for this purpose,
results may suggest that Idylla™MSI assay may be less depen-
dent on variations of pre-analytical conditions.
In summary, the Idylla™ MSI assay showed high concor-
dances with IHC and molecular testing, with a simple
workflow and short turnaround time. It required limited
860 Virchows Arch (2021) 478:851–863
amount of tumor tissue (nomatched normal tissue). This study
has been performed with the research use only product, as this
was the product available at that time. Currently, the company
has launched the CE-marked labeled in vitro diagnostic (IVD)
product.
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